GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Notes Receivable

ZBIO (Zenas BioPharma) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Notes Receivable?

Zenas BioPharma's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Zenas BioPharma Notes Receivable Historical Data

The historical data trend for Zenas BioPharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Notes Receivable Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Zenas BioPharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Zenas BioPharma Notes Receivable Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenas BioPharma Business Description

Traded in Other Exchanges
N/A
Address
852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.